Previously, our group has demonstrated that apremilast, a phosphodiesterase 4 inhibitor successfully used for the treatment of the disorder, increases IL-10 producing regulatory B cells and decreases IFNγ and IL-17 producing pro inflammatory T subsets in psoriasis and psoriatic arthritis patients [12]. Here, IL17A is linked to psoriatic arthritis.